US FDA approves Takeda’s Livtencity to treat people with post-transplant Cytomegalovirus infection EP News Bureau Nov 25, 2021 In the phase-III Solstice study, more than twice the proportion of adult transplant recipients with refractory or resistant (R/R)…
